New Prostate Cancer Drug Treatment May Increase Survival Time
Prostate cancer is the second most common cancer in men. New findings are that men diagnosed with advanced cases may live up to four months longer by taking a new chemotherapy drug. The drug is called Cabazitaxel. Cabazitaxel is the first drug to show a survival benefit in patients, whose disease has progressed after standard chemotherapy when all other options have been exhausted. Previously, hormone treatments were used to often reduce symptoms, but did not improve survival time. The only option until this recent study, was to administer mitoxantrone because of its beneficial effect on quality of life. The US has now given regulatory approval to Cabazitaxel.